Point of Care (POC) Diagnostics Market Overview

The Point of Care (POC) Diagnostics Market is poised for substantial growth between 2025 and 2035, fuelled by increasing prevalence of infectious diseases and technological advancements in point of care diagnostic market. Valued at approximately USD 49.6 billion in 2025, the market is projected to surge to USD 118.2 billion by 2035, reflecting a compound annual growth rate (CAGR) of 8.2% over the decade.

Point-of-care diagnostics provide a number of advantages by allowing patients to be diagnosed in various places including the doctor's office, in an ambulance, in the home, in the field, or in the hospital. Care is immediate and provides instant treatment to the patient. Diseases such as diabetes, rheumatism, and cancer are increasing worldwide for a variety of reasons including increased geriatric population, sedentary lifestyle, inappropriate diet, and environmental factors.

The rise in chronic and infectious conditions like diabetes, rheumatism, and malaria is on the rise across the world and is driving demand for point-of-care diagnostics. In December 2022, for example, World Health Organization (WHO) stated that malaria is a condition that can be deadly and that in 2021 there were estimated to be 247 million malaria cases across the globe. Moreover, advances in portable diagnostic equipment and telemedicine implementation are widening access to point-of-care diagnostics and allowing for real-time monitoring and on-time intervention.

Point of Care (POC) Diagnostics Market Drivers and Opportunities

Rising Prevalence of Chronic and Infectious Diseases is anticipated to lift the Point of Care (POC) Diagnostics Market during the forecast period

​The increasing incidence of chronic diseases such as diabetes, cardiovascular disease, and infectious diseases such as COVID-19, flu, and HIV/AIDS is a key driver for the market for point of care diagnostics. With patient volumes increasing for health systems, there is a greater need for rapid and reliable diagnostic tests. With instant results through point of care testing, clinical decision-making is expedient, hospital visits are reduced, and patient outcomes are improved. This is particularly relevant for disease management that is subject to ongoing monitoring, such as diabetes, for which continuous glucose monitoring (CGM) products have revolutionized patient management. In addition, the recent pandemic has fostered greater use of point of care diagnostic tests for respiratory infections and antimicrobial resistance, and this has driven point of care diagnostic market growth.

Technological Advancements and Miniaturization of Diagnostic Devices the growth of the global Point of Care (POC) Diagnostics Market

The increasing number of chronic diseases such as diabetes, cardiovascular disease, and infectious diseases such as HIV/AIDS, COVID-19, and flu is a key driver for the point-of-care diagnostics market. With rising patient volumes for health systems, there is greater demand for rapid and reliable diagnostic products. Point-of-care testing allows for immediate results that enable quicker clinical decision-making and reduce hospital visits and patient exposure. This is particularly relevant for disease control that requires ongoing monitoring such as diabetes for which products for continuous glucose monitoring (CGM) have revolutionized patient management. Further, recent outbreaks have increased point-of-care diagnostic test adoption for detection of respiratory infections and antimicrobial resistance as well, driving point of care diagnostic market growth.

Opportunity for the Point of Care Diagnostic Market

Expansion in Emerging Markets and Home Healthcare is poised to create significant opportunities in the global Point of Care (POC) Diagnostics Market

The Asia-Pacific, Latin American, and African emerging markets provide a great opportunity for POC diagnostics with expanding healthcare needs, rising disposable incomes, and government initiatives to improve health infrastructure. In rural and underdeveloped areas, centralized labs are not readily accessible and hence, POC testing is a crucial alternative for disease detection and management in a prompt manner. Further, the rising trend of home health care and self-testing with a growing population and patient demand for easy medical alternatives is widening the market even further. Companies that design low-cost and easy-to-use POC diagnostic products for these markets will be competitively placed and will create large revenue streams.

The trend is to be continued with health delivery changes that are meant to offer less costly care near home. In the developing world there is also a demand for more effective care for contagious diseases and PoCT can play a much greater role there in the future. PoCT equipment can be classified into two categories, but in both of them testing is usually done by equipment that was originally designed more than two decades ago.

Point of Care (POC) Diagnostics Market Scope

Point of Care (POC) Diagnostics Market Report Segmentation Analysis

The global Point of Care (POC) Diagnostics Market industry analysis is segmented into by Test Type, by Mode of Use, by Sample, by End-user, and by region.

The Infectious Disease Testing’s segment is anticipated to hold the highest share of the global Point of Care (POC) Diagnostics Market during the projected timeframe.

The Infectious Disease Testing segment is set to dominate the global Point of Care (POC) Diagnostics Market owing to increasing incidents of infectious diseases worldwide. Infectious diseases such as HIV, tuberculosis, flu, and COVID-19 are creating increased demand for rapid on-site diagnostic tests. Infectious disease tests for Point of Care provide instant results for immediate treatment and reduced infections. Expansion of decentralized testing in low-resource communities is also driving market growth. Improvements in test accuracy and efficiency through molecular diagnostic techniques and lateral flow assays drive market growth. Government support for disease detection at an early stage and inclusion of Point of Care testing in public health programs drive market growth. Along with this, a greater focus on pandemics preparedness has driven investment in this category. With the ability to provide immediate results bedside or in the field, POC tests are a preferred choice compared to time-consuming traditional laboratory tests.

The Blood sample segment is anticipated to hold the highest share of the market over the forecast period.

The Blood Sample segment is projected to hold the largest share in the global Point of Care (POC) Diagnostics Market on account of widespread use in disease diagnosis. Blood-based point of care tests are efficient in the detection of infections, chronic diseases, metabolic diseases, and cardiac diseases. They are very accurate and offer quick and reliable results and are therefore important for acute and chronic disease management. Rising rates of diabetes, cardiovascular disease, and haematological disease are also fueling demand for blood-based diagnostics.

Along with this, advancements in biosensors and microfluidics have made highly sensitive POCTs based on blood that reduce diagnosis time. Patient compliance has also been increased by ease of sampling through finger-prick methods in home and remote care. Increased application of portable blood analysers and greater focus on monitoring and detection of diseases in the initial stages contribute to dominance of this segment.

The Professional POC Testing segment dominated the market in 2024 and is predicted to grow at the highest CAGR over the forecast period.

The Professional POC Testing segment was a market leader in 2024 and is estimated to grow with the highest Compound Annual Growth Rate (CAGR) during the forecast period. This is primarily boosted by growing demand for tests in diagnostic centers, hospitals, and clinics, where prompt and reliable test results are crucial for immediate treatment. Medical professionals prefer point of care diagnostics for emergency conditions, critical care units, and operative areas, where rapid test results can make a significant difference to patient outcomes.

Rising chronic disease burden, including cardiovascular disease, diabetes, and respiratory disease, has boosted demand for ongoing monitoring, and this is also fueling the professional POC segment. Advances in portable analysers, molecular diagnostic equipment, and AI-based diagnostic equipment are enhancing test accuracy and efficiency. Government initiatives to promote early disease detection, preventive health, and greater availability of rapid tests in rural regions also fuel point of care diagnostics market growth.

The Hospitals & Clinics segment are predicted to grow at the highest CAGR over the forecast period.

The Hospitals & Clinics segment is anticipated to post the highest Compound Annual Growth Rate (CAGR) in the Point of Care (POC) Diagnostics Market through the forecast period. This is owing to increasing utilization of POC diagnostic equipment in hospitals, for which immediate test results are important for emergency and critical care management. Hospital and clinic-based POC testing enables faster diagnosis, faster decision-making, and reduced patient waiting times that improve health care efficiency and patient outcome.

The following segments are part of an in-depth analysis of the global Point of Care (POC) Diagnostics Market:

Point of Care (POC) Diagnostics Market Share Analysis by Region

North America is projected to hold the largest share of the global Point of Care (POC) Diagnostics Market over the forecast period.

The point of care diagnostics market is dominated by North America. Contributing to this dominance are continuous technological advancements such as miniaturized instruments and biosensors that facilitate rapid and reliable diagnosis. Strong government and private investment in research and development and increasing demand for decentralized health care products such as home test kits are also benefits of this region. High incidences of chronic and infectious diseases fuel demand for point-of-care diagnostic products in this region. Several RT-PCR systems based on microfluidics such as Cepheid GeneXpert have been granted clinical laboratory improvements amendments (CLIA) waivers by United States Food and Drug administration (FDA) for point-of-care use. Such systems utilize a single cassette with separate chambers for sample prep, amplification, and detection.

In addition to this, the Asia Pacific is also emerging as the fastest-growing market for POC diagnostics with a CAGR of 9.6% between 2024 and 2030. This is fuelled by increasing health expenditure, growing awareness of disease detection in an early stage and higher rates of chronic and infectious diseases such as diabetes and cardiovascular disease. Government policies to provide health care to rural areas and advancements in portable diagnostic equipment are key reasons for this growth.

Point of Care (POC) Diagnostics Market Competition Landscape Analysis

The market is competitive, with several established players and new entrants offering a range of Point of Care diagnostic products. Some of the key players include F. Hoffmann-La Roche Ltd., Qiagen, Danaher Corporation, Becton Dickinson (BD), bioMérieux, Abbott, Siemens Healthcare GmbH and others.

Global Point of Care (POC) Diagnostics Market Recent Developments News:

o   Indiana University and the Indiana Biosciences Research Institute are creating a joint center of excellence in September of 2024 that will utilize innovative technology, engineering and research to power personalized treatment for some of the globe’s most prevalent and complex diseases. The Joint Center of Excellence for Point of Care Precision Medicine will transform the health care system and improve patient care.

o   In August 2023, biotech start-up CrisprBits that deals with CRISPR gene-editing tech has forged a strategic alliance with Molbio Diagnostics. The reason for this alliance is to make inroads for CRISPR in Point-of-Care (POC) tests. With this strategic alliance between CrisprBits and Molbio Diagnostics, they are seeking to find and utilize market opportunities by synergizing each other's competences and capabilities.

o   Roche acquired GenMark Diagnostics for US$1.8 billion in March 2021 to expand its capability for multiplex testing. This deal was a reflection of growing consolidation in diagnostics.

The Global Point of Care (POC) Diagnostics Market is dominated by a few large companies, such as

·         F. Hoffmann-La Roche Ltd.

·         Qiagen

·         Danaher Corporation

·         Becton Dickinson (BD)

·         bioMérieux

·         Abbott

·         Siemens Healthcare GmbH

·         Werfen

·         Nova Biomedical

·         Trividia Health, Inc.

·         QuidelOrtho Corporation

·         Trinity Biotech

·         Sekisui Diagnostics

·         Orasure Technologies, Inc.

·         EKF Diagnostics Holdings plc.

·         Other Players